CN119562965A - 胰岛素融合蛋白 - Google Patents

胰岛素融合蛋白 Download PDF

Info

Publication number
CN119562965A
CN119562965A CN202380034373.8A CN202380034373A CN119562965A CN 119562965 A CN119562965 A CN 119562965A CN 202380034373 A CN202380034373 A CN 202380034373A CN 119562965 A CN119562965 A CN 119562965A
Authority
CN
China
Prior art keywords
fusion protein
proinsulin
canine
sequence
feline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380034373.8A
Other languages
English (en)
Chinese (zh)
Inventor
S·J·布斯菲尔德
M·J·威尔逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scott Biotechnology Co
Original Assignee
Scott Biotechnology Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scott Biotechnology Co filed Critical Scott Biotechnology Co
Publication of CN119562965A publication Critical patent/CN119562965A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202380034373.8A 2022-03-01 2023-03-01 胰岛素融合蛋白 Pending CN119562965A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263315296P 2022-03-01 2022-03-01
US63/315,296 2022-03-01
PCT/US2023/063510 WO2023168288A2 (en) 2022-03-01 2023-03-01 Insulin fusion protein

Publications (1)

Publication Number Publication Date
CN119562965A true CN119562965A (zh) 2025-03-04

Family

ID=87884362

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380034373.8A Pending CN119562965A (zh) 2022-03-01 2023-03-01 胰岛素融合蛋白

Country Status (11)

Country Link
US (1) US20250188144A1 (https=)
EP (1) EP4486796A4 (https=)
JP (1) JP2025507929A (https=)
KR (1) KR20240167718A (https=)
CN (1) CN119562965A (https=)
AU (1) AU2023228668A1 (https=)
CA (1) CA3245376A1 (https=)
CL (1) CL2024002605A1 (https=)
IL (1) IL315354A (https=)
MX (1) MX2024010693A (https=)
WO (1) WO2023168288A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120173090B (zh) * 2025-05-21 2025-07-29 华中农业大学 猫血清白蛋白突变体、及其cho细胞表达方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002364586A1 (en) * 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
US9505823B2 (en) * 2006-08-07 2016-11-29 TEV A Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
CA2676932C (en) * 2007-02-01 2015-11-24 Technion Research & Development Foundation Ltd. Albumin fibers and fabrics and methods of generating and using same
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
BR112014015156A2 (pt) * 2011-12-20 2020-10-27 Indiana University Research And Technology Corporation análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira
WO2022098906A1 (en) * 2020-11-04 2022-05-12 The Trustees Of The University Of Pennsylvania Viral vectors encoding canine insulin for treatment of metabolic diseases in dogs
AU2023228669A1 (en) * 2022-03-01 2024-09-19 Scout Bio, Inc. Viral vector genome encoding an insulin fusion protein

Also Published As

Publication number Publication date
JP2025507929A (ja) 2025-03-21
CA3245376A1 (en) 2023-09-07
US20250188144A1 (en) 2025-06-12
KR20240167718A (ko) 2024-11-27
WO2023168288A2 (en) 2023-09-07
AU2023228668A1 (en) 2024-09-19
WO2023168288A3 (en) 2023-09-28
MX2024010693A (es) 2024-12-06
EP4486796A4 (en) 2026-03-04
IL315354A (en) 2024-11-01
EP4486796A2 (en) 2025-01-08
CL2024002605A1 (es) 2025-07-11

Similar Documents

Publication Publication Date Title
JP7417277B2 (ja) 超長期作用性インスリン－ｆｃ融合タンパク質および使用方法
ES2332100T3 (es) Proteinas de fusion del fgf-21.
NZ286466A (en) Obese proteins, their production, use and conjugates thereof
US7223726B2 (en) Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
CN102516393B (zh) 胰岛素模拟肽融合蛋白和突变体及其应用
TW201934571A (zh) Ｆｇｆ２１變體、融合蛋白及其應用
JP2018007693A (ja) インターロイキン４およびインターロイキンを含む融合タンパク質
IE922570A1 (en) Tissue-selective insulin analogs
CN106117370B (zh) 高糖基化Exendin‑4及其类似物的融合蛋白、其制备方法和用途
CN115991793A (zh) 具有多重活性的融合蛋白及其应用
CN106432509A (zh) 一种治疗代谢疾病的重组人成纤维细胞生长因子21融合蛋白及其制备方法和应用
US10736970B2 (en) Polypeptide complex of titin-telethonin beta-pleated sheet structure as polypeptide drug carrier, method of using the polypeptide complex, and fusion protein complex thereof
CN119562965A (zh) 胰岛素融合蛋白
US20250388926A1 (en) Viral vector genome encoding an insulin fusion protein
EP4524250A1 (en) Nucleic acid construct comprising utr and use thereof
JP2025505131A (ja) ＩｇＡプロテアーゼトランケート、ＩｇＡプロテアーゼトランケートを含む融合タンパク質及びその用途
CN119173269A (zh) 用于递送glp-1受体激动剂融合物的aav载体
CN117899223A (zh) 以nup35基因和或以nup35蛋白作为作用靶点的物质的应用及组合物
CN118620086B (zh) 一种治疗糖尿病的融合蛋白及其应用
US20240182925A1 (en) Insulin gene therapy to treat diabetes
WO2026039341A1 (en) Fc fusion protein therapeutics for companion animal obesity and methods of use
US20260125672A1 (en) Nucleic acid construct comprising utr and use thereof
WO2026039359A1 (en) Fc fusion protein therapeutics for companion animal obesity and methods of use
HK40098913A (zh) 工程化α-GAL A肽及其功能变体和治疗法布里病的相关方法
HK40098913B (zh) 工程化α-GAL A肽及其功能变体和治疗法布里病的相关方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination